Table 1.

Reported patients with aseptic meningitis after COVID-19-vaccinations.

	Saito et al.	Lee	Reis Carneiro et al.	Tagini et al.	Dupon et al.	Current Case
Age/sex	42 y/female	18 y/male	62 y/female	late 20s/female	34 y/female	15 y/male
Vaccine	BNT162b2	BNT162b2	BNT162b2	mRNA-1273	BNT162b2	BNT162b2
Onset of symptoms #	7 days	3 weeks	1 day	1–2 weeks	6–8 h	10 days
Vaccine dose	1st	2nd	1st	2nd	2nd	2nd
Preexisting conditions	migraine	-	dyslipidemia, anxiety	polycystic ovary syndrome	-	knee surgery 1 month ago
Accompanying Symptoms	-	-	-	oral and genital aphthous ulcers, pseudofolliculitis, intracranial hypertension	joint pain in wrists, ankles and knees, petechiae on lower extremities	oral aphthous ulcers, pustular skin lesion, erythema nodosum-like lesions, joint effusion, vitreous floaters
C-reactive protein	9.85 mg/dL	0.74 mg/dL	n.r.	10.9 mg/dL	16.9 mg/dL	5.34 mg/dL
CSF pleocytosis	176/µL (64.1% mononuclear, 34.8% granular)	115/µL (99.1% mononuclear)	1st LP: 101/µL 2nd LP: 301/µL (100% lymphocytes)	27/µL (98% lymphocytes, 2% monocytes)	188/µL (lymphocytic pattern)	242/µL (55% mononuclear, 45% granular)
CSF protein level	35.7 mg/dL (ref. 0–45)	67.2 mg/dL (ref. 20–45)	1st LP: 154 (ref. 15–40) 2nd LP: 208 (ref. 15–40)	55.1 mg/dL (ref. 15–45)	n.r.	69.4 mg/dL (ref. 15–40)
CSF/serum Ig-indices	IgG normal (IgA and IgM n.r.)	n.r.	n.r.	n.r.	n.r.	IgA and IgM elevated IgG normal
cMRI	normal	subtle leptomeningeal enhancement	normal	intracranial hypertension	normal	subtle leptomeningeal enhancement
Immunusuppressive treatment	methylprednisolone	no	dexamethasone	colchicine, prednisone, (after 1.5 months AZA)	methylprednisolone	no
Recovery	complete	complete	complete	incomplete, persistent intracranial hypertension, retinitis after 1.5 months	complete	complete

n.r. = not reported; AZA = azathioprine; ^# = onset of meningitis-related symptoms.